IncellDx’s Quantitative Immuno-Oncology Assay OncoTect iO Published in New Study
IncellDx, Inc., a single cell, precision medicine company, today announced that the international peer-reviewed medical journal Cancer Immunology, Immunotherapy has published a manuscript entitled: “Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.” Dr. Bruce Patterson, MD, Founder and CEO explained that this is a novel, single cell approach to quantifying the expression of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) tumor samples. The methodology has been validated on both fine needle aspiration (FNA) and tumor biopsies. The samples are non-enzymatically homogenized into single cell suspensions using IncellDx’s IncellPREP™ kit yielding a single-cell sample before a formalin-fixed paraffin embedded (FFPE) block is made.
As Dr. Patterson explained, “We believe this objective quantitation of PD-L1 expression in tumor and immune cells in NSCLC will allow for better prediction of patient response to the new PD-1 immunotherapies within a work flow that is suited well for primary indications where the initial diagnosis may be made using several approaches to sampling the tumor. Further, the assay and sample preparation are automated allowing for same day turn around.”
The PD-L1 and PD-1 assay is the first release of IncellDx, Inc.’s newest family of single cell, multi-parametric molecular products called OncoTect® iO for immuno-oncology in a multitude of tissue types. The paper is now available online at http://link.springer.com/article/10.1007/s00262-016-1889-3 .
About IncellDx Inc.
IncellDx, Inc. is a single cell diagnostics company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The Company develops products designed to address pressing unmet clinical needs in the advancement of cancer care in addition to its virology products.
For more information, please visit www.incelldx.com .
Chris Meda, +1-650-777-7630
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
G-STAR14.12.2017 01:02 | pressemeddelelse
Global Game Exhibition 'G-STAR 2017' Ends with a Big Finale
NY-IFF13.12.2017 22:18 | pressemeddelelse
IFF Declares Dividend for Fourth Quarter 2017
AZ-LIMELIGHT-NETWORKS13.12.2017 20:20 | pressemeddelelse
Limelight Networks Enhances DDoS Security Services with Faster Mitigation of Malicious Website Attacks
CT-INTERACTIVE-BROKERS13.12.2017 18:17 | pressemeddelelse
Interactive Brokers Now Allowing Short Positions in Bitcoin Futures
IMMERVISION13.12.2017 13:49 | pressemeddelelse
Sunny Optics Officially Licenses ImmerVision Panomorph Lens Technology for Global Production
NY-SYNACOR13.12.2017 13:32 | pressemeddelelse
Synacor Launches Enhancements to Zimbra Communications and Collaboration Suite
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum